What We Know About a Potential COVID-19 Vaccine
One might be lured to think, based on current news stories, that a COVID-19 vaccine will be available quickly. In a Phase I trial, a little number of healthy volunteers get a dosage of the vaccine, and are then kept track of. For the Moderna trial, 45 volunteers in between the ages of 18 and 55 will get 2 doses of the vaccine and be kept track of over a period of 6 weeks. If this Phase I trial is effective, it will then be followed by Phase II and Phase III trials, in which more individuals, including a wider variety of ages, will be given doses of the vaccine and kept track of. For Phase II trials, numerous hundred individuals, who have the ages and qualities similar to those the vaccine is indicated for, will be provided dosages of the vaccine, and then kept track of for side effects.
One may be lured to believe, based on recent news stories, that a COVID-19 vaccine will be available quickly. If this Phase I trial is effective, it will then be followed by Phase II and Phase III trials, in which more people, consisting of a broader variety of ages, will be provided dosages of the vaccine and monitored. For Phase II trials, numerous hundred people, who have the ages and qualities comparable to those the vaccine is indicated for, will be offered dosages of the vaccine, and then kept an eye on for side effects.